Skin Cancer and Hyperthermia and Radiotherapy

The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).

Trial Details

NCT ID
NCT06384053
Phase
NA
Sponsor
Kantonsspital Winterthur KSW
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined
  • Radiotherapy (RT)
Locations (sample)
  • Aarau, Canton of Aargau, Switzerland|47.39254,8.04422
  • Winterthur, Canton of Zurich, Switzerland|47.50564,8.72413
  • Bern, Switzerland|46.94809,7.44744
  • Lucerne, Switzerland|47.05048,8.30635

Key Eligibility Criteria

  • Personally signed and dated written informed consent
  • Histologically confirmed invasive non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of any di…
  • ≥ T2 (TNM Classification 8th Edition)
  • Tumor thickness up to 2cm (Maximum Depth invasion and/or exophytic growth, measured on pathology report or imaging)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →